Several cytokines regulate thyroid function and may be involved in the pathogenesis of thyroid disorders, including euthyroid sick syndrome. Leukemia inhibitory factor (LIF), a neuroimmune pleiotropic cytokine, was measured to assess its role in hypothalamic-pituitarythyroid function. Mean circulating serum LIF levels in 10 hypothyroid patients [TSH, 23 Ϯ 0.5 mIU/L (mean Ϯ SEM); free T 4 , 0.77 Ϯ 0.1 ng/dL] was 0.29 Ϯ 0.04 ng/mL, 145% higher (P Ͻ 0.04) than in 20 normal subjects (LIF, 0.20 Ϯ 0.02 ng/mL; TSH, 2.23 Ϯ 0.21 mIU/L; free T 4 , 1.23 Ϯ 0.04 ng/dL) but was not different from those in 10 hyperthyroid patients (LIF, 0.21 Ϯ 0.03 ng/mL; TSH, 0.01 Ϯ 0.00 mIU/L; free T 4 , 3.63 Ϯ 0.51 ng/dL). Serum LIF concentrations linearly correlated with serum TSH in the 40 samples (r ϭ 0.58, P Ͻ 0.001). When T 4 (1-8 g/kg⅐day) was administered to cynomolgus monkeys with methimazole-induced hypothyroidism, serum T 4 and T 3 levels increased appropriately, and TSH and LIF concentrations decreased. When methimazole was given alone, both serum TSH (146 Ϯ 30 mIU/L) and LIF (8.84 Ϯ 0.49 ng/mL) were markedly induced. When methimazole together with T 4 (Ͼ2 g/kg⅐day) was administered, both serum TSH (7.5 Ϯ 1.2 mIU/L) and LIF (6.22 Ϯ 0.31 ng/mL) were lowered (P Ͻ 0.01). Monkey serum LIF levels and log TSH levels also correlated (r ϭ 0.72, P Ͻ 0.01). Cultured thyroid carcimona cells produced LIF (9.2 ng/10 6 cells/48 h). TSH (100 mIU/mL) and interleukin (IL)-6 (10 nmol/L) stimulated in vitro LIF secretion from the cells by 170 Ϯ 12% (P Ͻ 0.05) and 261 Ϯ 8% (P Ͻ 0.05), respectively. Dexamethasone (1 mol/L) inhibited basal LIF concentration by 83% (P Ͻ 0.05), whereas TSH and IL-6 stimulated LIF by 52% (P ϭ 0.04) and 42% (P ϭ 0.03), respectively. However, using Northern blot analysis, we could not observe induction of LIF mRNA by TSH, suggesting that LIF regulation by TSH may be due to stimulation of secretion. The results show that the thyroid gland is a source of LIF production; TSH, IL-6, and glucocorticoid influence thyroid cell LIF expression. The correlation between TSH and LIF suggests that LIF may participate in the physiologic regulation of hypothalamic-pituitary-thyroid function. (J Clin Endocrinol
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Leukemia inhibitory factor (LIF) is an important member of the cytokine family (6). Our previous studies have shown that human and murine pituitary cells express the LIF gene and LIF-binding sites (7, 8) , and LIF synergizes with CRH induction of POMC transcription, resulting in a striking increase in ACTH secretion from pituitary cells in vitro, as well as in vivo (8 -10) .
In this study, we assessed the role of LIF in hypothalamicpituitary-thyroid function, including an examination of LIF production and regulation in isolated thyrocytes.
Materials and Methods

Human subjects
Blood samples were obtained from normal subjects and hypothyroid or hyperthyroid patients before treatment. Serum was stored at Ϫ20 C until assay for LIF, TSH, free T 4 , and T 3 levels.
Primate studies
Monkey sera were obtained from a previous study of thyroid function (11) . Briefly, after 12 weeks of baseline studies, five male and five female cynomolgus monkeys, 2-2.5 yr old, were rendered hypothyroid by addition of 0.0125% methimazole to their drinking water for the ensuing duration of the study. After 12 weeks of methimazole administration, each animal received exogenous T 4 (1, 2, 4, or 8 g/kg⅐day), for 9 weeks, with intervals of 6 weeks between successive T 4 doses. Blood was collected every 3 weeks during the baseline period, the methimazole-only period, and each T 4 dose treatment period. Results from serum assayed during each baseline and treatment period were individually averaged to obtain the mean level during the corresponding period for each animal. Serum was stored at Ϫ20 C until assays for TSH, T 4 , T 3 , and LIF levels.
Cell culture
A human thyroid carcinoma cell line BHP 18 (12) was cultured in 6-multiwell culture plates or 75-cm 2 flasks (Life Technologies, Gaithersburg, MD) containing RPMI-1640 medium (Life Technologies) supplied with 10% FBS and antibiotics. When cells were confluent, medium was removed, and cells were exposed, for an additional 48 h, to serumfree RPMI-1640 medium containing either 0.1% ethanol or 1 mol/L dexamethasone (dissolved in ethanol; final concentration of ethanol was 0.1%), without or with 100 mU/mL TSH (Sigma Chemical Co., St. Louis, MO) or 10 nmol/L IL-6 (R&D Systems, Minneapolis, MN). At the end of the experiment, the medium was removed, centrifuged, and stored at Ϫ20 C until assay. Cells were then counted or RNA extracted.
LIF measurement
LIF, in serum or culture medium, was measured in duplicate by RIA, as previously described (13) . Escherichia coli-derived recombinant human (h)LIF and goat polyclonal anti-hLIF antibody were purchased (R&D Systems), and LIF was iodinated using an iodogen (Pierce Chemical Co., Rockford, IL) method (14) . The sensitivity was 0.05 ng/mL. Intraassay variations were 7% at 50 ng/mL and 4% at 6 ng/mL. Interassay variations were 3% at 50 ng/mL and 11% at 6 ng/mL. As we previously mentioned, LIF standard is not available and LIF levels measured by this RIA should be considered relative immunoreactive values (13); therefore, LIF values for comparison in each group were measured in a single assay. Serial dilutions of monkey serum were assayed by hLIF RIA, and the observed LIF values were parallel to the human standard curve (r ϭ 0.996, P Ͻ 0.004), indicating that the hLIF RIA measured immunoreactive LIF in monkey serum.
TSH, thyroid hormones measurement
Human serum TSH, free T 4 , and total T 3 values were measured with the IMX System using the microparticle enzyme immunoassay technology of Abbott Laboratories (Abbott Park, IL), as previously described (15, 16) . Monkey serum TSH, T 4 , and T 3 levels were measured in duplicate by RIA at Hazleton Laboratories (Vienna, VA), as previously described (11) . Human TSH as standard and labeled ligand and antihuman-TSH serum were used in the TSH RIA, which recognized monkey TSH.
Northern blot
LIF gene expression in the thyroid carcinoma cell line was measured by Northern blot method, as previously described (7) 
Statistics
Results are expressed as mean Ϯ sem. Student's t test was used to compare results, and correlation coefficients were determined by linear regression analysis.
Results
Mean circulating serum LIF levels in 10 hypothyroid patients was 0.29 Ϯ 0.04 ng/mL, 145% higher (P Ͻ 0.05) than in 20 normal subjects (0.20 Ϯ 0.02 ng/mL) but not different from values in 10 hyperthyroid patients (0.21 Ϯ 0.03 ng/mL). Serum TSH, free T 4 , T 3 , and LIF concentrations in 3 groups are listed in Table 1 . Serum LIF concentrations correlated with serum TSH levels in the 40 samples (r ϭ 0.58, P Ͻ 0.001), as shown in Fig. 1 , but did not correlate with free T 4 or T 3 levels. The correlation coefficients between free T 4 and T 3 was 0.89 (P Ͻ 0.001); and between free T 4 and TSH, it was Ϫ0.35 (P ϭ 0.011).
In the monkey study, when methimazole was given alone, both serum LIF and TSH were markedly increased (by 130% and 2300%, respectively), and T 4 and T 3 levels were significantly reduced, compared with baseline. When T 4 (1-8 g/ kg⅐day) was administered to cynomolgus monkeys with methimazole-induced hypothyroidism, serum T 4 and T 3 levels increased appropriately, and TSH and LIF concentrations decreased. When the exogenous T 4 dose was greater than 2 g/kg⅐day, both serum LIF and TSH levels were reduced, respectively, to 70 and 5% of values observed during hypothyroidism. The dose-response relationships between the exogenous T 4 dose and the serum LIF, TSH, T 4 , and T 3 levels are shown in Table 2 . Mean serum LIF levels and TSH levels during each period also correlated (r ϭ 0.72, P Ͻ 0.01) (Fig. 2) .
Cultured thyroid carcinoma cells produced 9.2 ng LIF/10 6 cells⅐48 h. TSH (100 mIU/mL) and IL-6 (10 nmol/L) stimulated in vitro LIF secretion from the cells by 170 Ϯ 12% (P Ͻ 0.05) and 261 Ϯ 8% (P Ͻ 0.05), respectively. Dexamethasone (1 mol/L) inhibited basal LIF concentration by 53%, whereas TSH and IL-6 stimulated LIF by 52% (P Ͻ 0.05) and 42% (P Ͻ 0.05), respectively, as shown in Fig. 3 . Northern blot analysis indicated that LIF was expressed in the thyroid cell line, but not regulated by a wide range of TSH examined at different time points, suggesting that TSH may stimulate LIF-secretion but not its synthesis.
Discussion
The results indicate that hypothyroidism is associated with elevated serum LIF levels. Untreated hypothyroid patients had significantly higher serum LIF levels than normal subjects (Table 1) . Serum LIF levels in monkeys with methimazole-induced hypothyroidism were markedly ele- vated, compared with normal, and this increase in LIF concentration was reversed with exogenous T 4 doses greater than 2g/kg⅐day (Table 2) . Hyperthyroidism, however, is not associated with either higher or lower serum LIF levels in humans. When 8 g/kg⅐day T 4 was given to monkeys, TSH was markedly reduced, T 3 and T 4 were significantly increased (compared with baseline), but serum LIF did not differ from baseline (Table 2) . From our data, however, we could not determine the initial abnormality in LIF, TSH, and thyroid hormones that results in high serum LIF and TSH levels and low thyroid hormone concentrations. The reason for high serum LIF levels in hypothyroidism remains unclear. One explanation is that low thyroid hormone levels induced TSH, which stimulated thyroid LIF release. Therefore, elevated serum LIF concentrations, observed in hypothyroid patients and monkeys, may be caused by enhanced LIF secretion from thyroid cells stimulated by TSH. This hypothesis is suggested by the significant correlation between serum LIF and TSH levels in both patients and monkeys ( Figs. 1 and 2 ) and the stimulation by TSH of LIF secretion from human thyroid carcinoma cells (Fig. 3) . Our results detecting LIF production in thyroid cells and its stimulation by TSH are similar to those of studies with IL-6, which has been shown to be produced by the thyroid gland (3) and stimulated by TSH (17) . However, this hypothesis should be further confirmed by testing in more thyroid cell lines with a wide range of TSH doses. Nevertheless, TSH seems to be an LIF regulator, because low levels of TSH seen in hyperthyroidism did not alter mean serum LIF levels, compared with baseline.
Alternatively, high LIF levels may inhibit thyroid hormone production, which, in turn, induces TSH secretion. Although our data could not directly support this hypothesis, studies on other members of the related family of pleiotropic cytokines (including OSM, IL-6, and IL-11) provided indirect evidence. Although these individual cytokines have unique biological functions, they also have common functions and share a common signal transducer gp-130 (1, 2, 5, 18). For example, IL-6 suppresses thyroid peroxidase gene expression and T 3 secretion from cultured human thyrocytes (19) , and administration of IL-6 into humans decreases plasma T 3 concentrations (20) . In an investigation of 270 hospital inpatients with nonthyroidal illness, a significant negative correlation between serum total T 3 and IL-6, and total T 4 and IL-6 were observed (21) . IL-6 also may decrease TSH levels in vivo (20, 21) . Furthermore, TNF inhibited thyroid function (4), and decreased serum T 3 levels and decreased serum free T 4 levels were associated with increased circulating levels of TNF in nonthyroid disease patients (22, 23) . Recently, OSM and IL-6, as well as LIF, were shown to inhibit iodide uptake stimulated by TSH in cultured thyroid cells (5) . Using a RT-PCR technique, gp-130 and LIF receptor ␤-subunit mRNA were detected in porcine thyroid cells (5) . Together, these data suggest that LIF may function to suppress thyroid hormone production. In our study, however, thyroid hormone synthesis in monkey thyroid was initially inhibited by methimazole, followed by increases of LIF and TSH levels. Therefore, even if LIF has any inhibitory action on thyroid hormone production, it should be considered as a secondary-effect-mediated autocrine mechanism. Another possibility is that LIF synthesis is under negative feedback control by thyroid hormone and low levels of thyroid hormone releases the inhibition of LIF, as well as TSH, resulting in elevated concurrent LIF and TSH production. LIF is produced from multiple cell types, including endometrium, bone marrow stromal, thymic, lymphocytes, pituitary, and thyroid (2, 24, 25) , and thyroid hormone functions in multiple cell types. It is unknown whether thyroid hormone inhibits LIF production from these cells. Although the pituitary is a known source of LIF (7, 24) , the concentrations are in picogram quantities per pituitary (13) , whereas the thyroid cells produce nanogram quantities of LIF, making it more likely that the thyroid (not the pituitary) is the source of serum LIF in this study. Our unpublished data also showed that T 4 (10 g/mL) could not inhibit LIF production in the BHP 18 human thyroid carcinoma cell line.
LIF is cleared rapidly from the circulation. Studies showed that murine LIF injected ip into adult mice has an initial half-life of 6 -8 min and a prolonged secondary clearance phase of several hours. The clearance of murine LIF from the circulation is paralleled by accumulation of LIF in the kidneys, liver, lung, spleen, and thyroid gland; and kidneys are the major route of LIF clearance (26) . Patients with hypothyroidism have low metabolic rates. Therefore, it is also possible that the clearance rate of LIF in hypothyroidism patients is slower, resulting in higher serum LIF levels.
Previous studies have shown that IL-1␣, IL-1␤, or TNF-␣ induces LIF gene expression in fibroblasts (27) , bone marrow cells (28) , endometrial cells (29) , and pituitary cells (30) . It also has been reported that LIF gene expression is stimulated by IL-6 (6) and inhibited by dexamethasone in rat anterior pituitary (31) . The results shown here indicate that regulation of LIF by these agents also occurs in the thyroid gland.
In summary, our results indicate that the thyroid gland is a source of LIF production and that IL-6, glucocorticoids, and TSH influence LIF secretion in cultured thyroid cells. Moreover, the strong correlation between serum TSH and LIF levels suggests that LIF may be involved in the physiology and pathology of hypothalamic-pituitary-thyroid function.
